170 related articles for article (PubMed ID: 29549642)
21. Crystal structure of a cocaine-binding antibody.
Larsen NA; Zhou B; Heine A; Wirsching P; Janda KD; Wilson IA
J Mol Biol; 2001 Aug; 311(1):9-15. PubMed ID: 11469854
[TBL] [Abstract][Full Text] [Related]
22. Protein-peptide docking: opportunities and challenges.
Ciemny M; Kurcinski M; Kamel K; Kolinski A; Alam N; Schueler-Furman O; Kmiecik S
Drug Discov Today; 2018 Aug; 23(8):1530-1537. PubMed ID: 29733895
[TBL] [Abstract][Full Text] [Related]
23. Structure versus function-The impact of computational methods on the discovery of specific GPCR-ligands.
Bermudez M; Wolber G
Bioorg Med Chem; 2015 Jul; 23(14):3907-12. PubMed ID: 25828056
[TBL] [Abstract][Full Text] [Related]
24. Structure-based drug metabolism predictions for drug design.
Sun H; Scott DO
Chem Biol Drug Des; 2010 Jan; 75(1):3-17. PubMed ID: 19878193
[TBL] [Abstract][Full Text] [Related]
25. Human IgG1 Cgamma1 domain is crucial for the bioactivity of the engineered anti-CD20 antibodies.
Geng S; Feng J; Li Y; Kang X; Sun Y; Gu X; Huang Y; Chang H; Shen BF
Cell Mol Immunol; 2007 Apr; 4(2):121-5. PubMed ID: 17484806
[TBL] [Abstract][Full Text] [Related]
26. Computational discovery of novel HIV-1 entry inhibitors based on potent and broad neutralizing antibody VRC01.
Andrianov AM; Kashyn IA; Tuzikov AV
J Mol Graph Model; 2015 Sep; 61():262-71. PubMed ID: 26298811
[TBL] [Abstract][Full Text] [Related]
27. Molecular modeling of cardiac glycoside binding by the human sequence monoclonal antibody 1B3.
Paula S; Monson N; Ball WJ
Proteins; 2005 Aug; 60(3):382-91. PubMed ID: 15971203
[TBL] [Abstract][Full Text] [Related]
28. In silico design of small peptides antagonist against leptin receptor for the treatment of obesity and its associated immune-mediated diseases.
Munikumar M; Krishna VS; Reddy VS; Rajeswari B; Sriram D; Rao MV
J Mol Graph Model; 2018 Jun; 82():20-36. PubMed ID: 29649778
[TBL] [Abstract][Full Text] [Related]
29. Applications of computer-aided approaches in the development of hepatitis C antiviral agents.
Ganesan A; Barakat K
Expert Opin Drug Discov; 2017 Apr; 12(4):407-425. PubMed ID: 28164720
[TBL] [Abstract][Full Text] [Related]
30. Advances in Antibody Design.
Tiller KE; Tessier PM
Annu Rev Biomed Eng; 2015; 17():191-216. PubMed ID: 26274600
[TBL] [Abstract][Full Text] [Related]
31. Computational Tools for Aiding Rational Antibody Design.
Krawczyk K; Dunbar J; Deane CM
Methods Mol Biol; 2017; 1529():399-416. PubMed ID: 27914064
[TBL] [Abstract][Full Text] [Related]
32. Application of Computational Techniques to Unravel Structure-Function Relationship and their Role in Therapeutic Development.
Yadav TC; Srivastava AK; Dey A; Kumar N; Raghuwanshi N; Pruthi V
Curr Top Med Chem; 2018; 18(20):1769-1791. PubMed ID: 30465508
[TBL] [Abstract][Full Text] [Related]
33. Antibody Affinity Maturation by Computational Design.
Kuroda D; Tsumoto K
Methods Mol Biol; 2018; 1827():15-34. PubMed ID: 30196490
[TBL] [Abstract][Full Text] [Related]
34. Computer-aided drug design to explore cyclodextrin therapeutics and biomedical applications.
Abdolmaleki A; Ghasemi F; Ghasemi JB
Chem Biol Drug Des; 2017 Feb; 89(2):257-268. PubMed ID: 28205401
[TBL] [Abstract][Full Text] [Related]
35. Overview on the current status on virtual high-throughput screening and combinatorial chemistry approaches in multi-target anticancer drug discovery; Part II.
Geromichalos GD; Alifieris CE; Geromichalou EG; Trafalis DT
J BUON; 2016; 21(6):1337-1358. PubMed ID: 28039691
[TBL] [Abstract][Full Text] [Related]
36. Lead optimization via high-throughput molecular docking.
Joseph-McCarthy D; Baber JC; Feyfant E; Thompson DC; Humblet C
Curr Opin Drug Discov Devel; 2007 May; 10(3):264-74. PubMed ID: 17554852
[TBL] [Abstract][Full Text] [Related]
37. [An introduction to the computer-aided structure-based drug design--applications of bioinformatics to drug discovery].
Hirono S
Rinsho Byori; 2002 Jan; 50(1):45-51. PubMed ID: 11871136
[TBL] [Abstract][Full Text] [Related]
38. Computer-aided design of GPCR ligands.
Gutiérrez-de-Terán H; Keränen H; Azuaje J; Rodríguez D; Åqvist J; Sotelo E
Methods Mol Biol; 2015; 1272():271-91. PubMed ID: 25563191
[TBL] [Abstract][Full Text] [Related]
39. Immunology. Two-in-one designer antibodies.
Parren PW; Burton DR
Science; 2009 Mar; 323(5921):1567-8. PubMed ID: 19299606
[No Abstract] [Full Text] [Related]
40. Pharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies.
Leipold D; Prabhu S
Clin Transl Sci; 2019 Mar; 12(2):130-139. PubMed ID: 30414357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
